CorVel Corporation (CRVL)
NASDAQHealth CareInsurance - BrokersSnapshot 2026-09-04
$68.23-0.66%
Close 2026-09-04 · 1-day change
NASDAQHealth CareInsurance - BrokersSnapshot 2026-09-04
QuarterlyIQ Insights · CRVL
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks CRVL against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Met or beat guidance 100% of the last 1 guided quarters · 28.7% avg surprise
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Broaden CERIS payment integrity capabilities with new client implementations and targeted investments to improve payment accuracy and address cost and regulatory pressures.
Stated as a priority in 3 of last 3 quarters. Revenue grew from $235 million in 2025-Q4 to $260 million in 2026-Q2, reflecting an 11% increase. Management consistently emphasized expanding CERIS prepay solutions with new client implementations and investments to improve payment accuracy, showing delivering progress.
“CERIS broadened its payment integrity capabilities through new client implementations and targeted investments designed to improve payment accuracy.”
“CERIS is benefiting from the healthcare industry’s shift toward proactive payment accuracy and cost management, with strong demand for its integrated prepay and post-pay platform.”
“CERIS ongoing technology enhancements address rising medical costs, increased regulatory scrutiny, and vendor consolidation by combining clinical expertise with AI-enabled workflows.”
Advance AI initiatives across products, services, and internal processes to improve efficiency, augment operations, and enhance outcomes for partners.
Stated as a priority in 3 of last 3 quarters. Management highlighted AI and automation investments improving efficiency and outcomes, supporting revenue growth from $235 million in 2025-Q4 to $260 million in 2026-Q2. The trajectory shows delivering progress with material advances in AI initiatives.
“Ongoing investments in automation, telemedicine, cybersecurity, and API-driven connectivity strengthen scalability and consistent results.”
Advance technology-enabled, clinically integrated P&C services through AI, real-time data integration, and embedded clinical expertise to improve claims outcomes.
Stated as a priority in 3 of last 3 quarters. Management emphasized advancing P&C services with AI and data integration to improve claims outcomes. Revenue increased from $228 million in 2024-Q4 to $260 million in 2026-Q2, supporting the focus on strengthening P&C services. The trajectory is delivering progress.
Maintain disciplined capital management with ongoing share repurchases and strong cash position to support long-term value creation.
Stated as a priority in 3 of last 3 quarters. The company repurchased $20.1 million in 2025-Q4 and $21.8 million in 2026-Q2, while cash increased from $233 million in 2026-Q1 to $256 million in 2026-Q2. Management has maintained disciplined capital management with ongoing share repurchases and strong liquidity, delivering on stated priorities.
Complete leadership transition with Sarah Scott appointed CEO and President, continuing long-term vision and strategic priorities.
Newly stated in 2026-06-01 press release. The leadership transition to Sarah Scott as CEO and President was announced effective July 1, 2026, with Michael G. Combs moving to Executive Chair. This priority is recent and no financial impact data is yet available.
Over the trailing year it converted 1.47x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 55% of the time over the next year (vs 45% for the rest of the cohort, n=2490).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
4 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.
“CERIS is accelerating revenue realization cycles while maintaining strong margin profiles, supported by ongoing investment in AI and automation.”
“AI initiatives advanced materially across the organization, delivering tangible benefits across products, services, and internal development processes.”
“P&C services are advancing its technology-enabled, clinically integrated model through AI, real-time data integration, and embedded clinical expertise.”
“Investments in automation, telemedicine, cybersecurity, and API-driven connectivity strengthen scalability and consistent clinical and financial results.”
“In P&C, the intentional application of intelligence, automation, and modernized data exchange is delivering a simpler, more accurate claims experience.”
“The Company repurchased $21.8 million of common stock during the quarter and exited with $256 million of cash, no borrowings.”
“Exited the quarter with $233 million of cash, cash equivalents, and no borrowings.”
“The Company repurchased $20.1 million of common stock during the quarter and exited with $233 million of cash, no borrowings.”